Bruker Corporation - BRKR STOCK NEWS

Bruker Corporation has unveiled the timsTOF HT system at the 70th ASMS meeting, enhancing its 4D Multiomics platform with a fourth-generation TIMS XR cell and a 14-bit digitizer. This innovation boosts dynamic range and peptide coverage, enabling the identification of over 100,000 unique peptides with high quantification accuracy. The system supports high-throughput proteomics, achieving sample processing rates of up to 200 samples per day. Additionally, the PaSER mode allows real-time data streaming for intelligent acquisition, further advancing metabolomics and biomarker discovery.

Bruker Corporation (NASDAQ: BRKR) has expanded its mass spectrometry capabilities by acquiring IonSense, the developer of DART™ technology, enhancing Point-of-Need (PoN) analysis. The newly launched DART-EVOQ® triple quadrupole mass spectrometer allows quick analyses across various sectors like food, forensics, and pharmaceuticals without the need for chromatography. Additionally, Bruker has partnered with TOFWERK AG to accelerate the development of high-speed analytical solutions. These strategic moves aim to position Bruker as a leader in PoN mass spectrometry.

Bruker Corporation (Nasdaq: BRKR) will present at the Jefferies 2022 Global Healthcare Conference in New York on June 9, 2022, at 3:00 pm EDT. Frank Laukien, CEO, and Justin Ward, Sr. Director of Investor Relations, will represent the company. A live audio webcast will be available on the Investor Relations section of Bruker's website, with a replay accessible for 30 days post-event. Bruker is dedicated to advancing scientific discovery and enhancing human life through its innovative analytical solutions and high-performance scientific instruments.

Bruker Corporation (NASDAQ: BRKR) announced the approval of a quarterly cash dividend of $0.05 per share. This dividend will be paid on June 17, 2022, to stockholders of record as of June 1, 2022.

Bruker is dedicated to advancing scientific discovery through high-performance instruments and analytical solutions that enhance human life quality. The company operates in various domains including life sciences, applied markets, and industrial applications.

Bruker Corporation (BRKR) has entered a strategic partnership with TOFWERK AG, including a minority investment by Bruker in TOFWERK. This collaboration focuses on enhancing high-speed and ultra-sensitive analytical solutions, particularly in mass spectrometry for small molecules and volatile compounds. The partnership aims to leverage Bruker’s commercial scale to boost TOFWERK’s market presence. Innovations include advanced instrument capabilities and applications for ambient air analysis, breath diagnostics, and semiconductor monitoring.

Bruker Corporation reported Q1 2022 revenues of $595.0 million, a 7.3% year-over-year increase. Organic revenue growth was notable at 10.5%. The company saw GAAP diluted EPS rise to $0.41, up from $0.37 in Q1 2021. With strong demand for its life science tools, Bruker raised its FY 2022 organic revenue outlook to 7% to 9% and expects non-GAAP EPS between $2.29 to $2.33, reflecting a 9% to 11% increase year-over-year. The firm also made key acquisitions to bolster growth.

Bruker recently showcased its innovative Ascend Evo 1.0 GHz NMR magnet at the Experimental Nuclear Magnetic Resonance Conference, designed to operate at 4.2 Kelvin for structural biology in standard labs. This new technology boasts a significant reduction in liquid helium consumption by threefold, enhancing accessibility for researchers. Additionally, Bruker introduced the Heliosmart Recovery system which enables the collection of helium gas boil-off, achieving recovery rates of 80%-85%. The company continues to offer services like LabScape Remote Monitoring for effective management of NMR magnets.

Bruker Corporation (Nasdaq: BRKR) recently introduced advancements in its MALDI Biotyper® platform and launched new multiplex PCR assays at the 32nd European Congress of Clinical Microbiology & Infectious Diseases. Key offerings include the FluoroType® Mycobacteria PCR assay, which differentiates 32 mycobacteria species, and the FluoroType® STI PCR assay, which detects seven major STI pathogens. These innovations enhance Bruker's portfolio in infectious disease diagnostics, leveraging its LiquidArray® technology for improved accuracy and speed in clinical settings.